Advances in clinical research on novel coronavirus infections combined with venous thromboembolism： based on current evidence-based evidence

doi:10.3969/j.issn.1009-976X.2023.02.015

Abstract

Abstract: Novel coronavirus infection can easily cause a disturbance in the body's coagulation function, leading to the occurrence of venous thromboembolism（VTE）. Anticoagulation therapy based on low-molecular heparin（LMWH） is currently the preferred method for thrombosis prevention and treatment, and it is of great clinical significance to evaluate and perform early scientific and rational thrombosis prevention in combination with an advanced and well-developed scoring system.This article provides a comprehensive review of the clinical research progress on novel coronavirus infection combined with VTE, providing more decision-making references for clinical doctors treating such patients.

Key words: novel coronavirus infection, venous thromboembolism, anticoagulation

摘要： 新型冠状病毒感染容易引起机体内凝血功能紊乱,从而导致新冠感染患者发生静脉血栓栓塞症（VTE）的风险比普通人大大增加。以低分子肝素（LMWH）为主的抗凝治疗为目前血栓防治的首选方法,结合先进、完善的评分体系进行评估并及早进行科学、合理的血栓预防具有重大的临床意义。本文对目前新型冠状病毒感染合并VTE的临床研究进展进行综述,为临床医生诊治该类患者提供相应的决策参考。

关键词: 新型冠状病毒感染, 静脉血栓栓塞症, 抗凝治疗

CLC Number:

R654.3

XU Jia-tang, CAO Lin, ZENG Xiao-ying, SHEN Run-nan, YOU Guo-chang, HUANG Kai. Advances in clinical research on novel coronavirus infections combined with venous thromboembolism： based on current evidence-based evidence[J]. Lingnan Modern Clinics In Surgery, 2023, 23(02): 200-204.

徐嘉堂, 曹淋, 曾晓莹, 沈润楠, 尤国昌, 黄楷. 新型冠状病毒感染合并静脉血栓栓塞症的临床研究进展——基于当前的循证证据[J]. 岭南现代临床外科, 2023, 23(02): 200-204.

References

[1] Stein SR, Ramelli SC, Grazioli A, et al.SARS-CoV-2 infection and persistence in the human body and brain at autopsy[J]. Nature, 2022, 612(7941): 758-763.
[2] Hippisley-Cox J, Patone M, Mei XW, et al.Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study[J]. BMJ, 374:n1931.
[3] Suzuki R, Yamasoba D, Kimura I, et al.Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 603(7902): 700-705.
[4] Olaf M, Cooney R.Deep Venous Thrombosis[J]. Emerg Med Clin North Am, 2017, 35(4): 743-770.
[5] Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort [J]. Am J Med, 2013, 126(9): 832.e13-21.
[6] Silverstein MD, Heit JA, Mohr DN, et al.Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study[J]. Arch Intern Med, 1998, 158(6): 585-93.
[7] Ortel TL, Neumann I, Ageno W, et al.American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv, 2020, 4(19): 4693-4738.
[8] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[9] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.
[10] Bilaloglu S, Aphinyanaphongs Y, Jones S, et al.Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System[J]. Jama, 2020, 324(8): 799-801.
[11] Ackermann M, Verleden SE, Kuehnel M, et al.Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19[J]. N Engl J Med, 2020, 383(2): 120-128.
[12] Wichmann D, Sperhake JP, Lütgehetmann M, et al.Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study[J]. Ann Intern Med, 2020, 173(4): 268-277.
[13] Menter T, Haslbauer JD, Nienhold R, et al.Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction[J]. Histopathology, 2020, 77(2): 198-209.
[14] Kollias A, Kyriakoulis KG, Lagou S, et al.Venous thromboembolism in COVID-19: A systematic review and meta-analysis[J]. Vasc Med, 2021, 26(4): 415-425.
[15] Raisi-Estabragh Z, Cooper J, Salih A, et al.Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank[J]. Heart, 2022, 109(2): 119-126.
[16] Kompaniyets L, Bull-Otterson L, Boehmer TK, et al.Post-COVID-19 Symptoms and Conditions Among Children and Adolescents - United States, March 1, 2020-January 31, 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(31): 993-999.
[17] Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al.Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study[J]. BMJ, 2022, 377: e069590.
[18] 宋景春. 新型冠状病毒凝血病与免疫血栓[J]. 血栓与止血学, 2022, 28(01): 2001-2006.
[19] Conway EM, Mackman N, Warren RQ, et al.Understanding COVID-19-associated coagulopathy[J]. Nat Rev Immunol, 2022, 22(10): 639-649.
[20] Navarrete S, Solar C, Tapia R, et al. Pathophysiology of deep vein thrombosis [J]. Clin Exp Med, 2022;10.1007/s10238-022-00829-w.
[21] Albani F, Sepe L, Fusina F, et al.Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study[J]. EClinicalMedicine, 2020, 27: 100562.
[22] Zhai Z, Li C, Chen Y, et al.Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines[J]. Thromb Haemost, 2020, 120(6): 937-948.
[23] Heit JA, Silverstein MD, Mohr DN, et al.The epidemiology of venous thromboembolism in the community[J]. Thromb Haemost, 2001, 86(1): 452-463.
[24] Manne BK, Denorme F, Middleton EA, et al.Platelet gene expression and function in patients with COVID-19[J]. Blood, 2020, 136(11): 1317-1329.
[25] Begbie M, Notley C, Tinlin S, et al.The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP[J]. Thromb Haemost, 2000, 84(2): 216-222.
[26] Wang T, Chen R, Liu C, et al.Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19[J]. Lancet Haematol, 7(5): e362-e363.
[27] 北京协和医院呼吸与危重症医学科新冠肺炎诊疗参考方案(2022年12月版)[J]. 2022.
[28] 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 全国肺栓塞与深静脉血栓形成防治能力建设项目办公室. 新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J]. 中华医学杂志, 2020. https://rs.yiigle.com/CN112137202011/1186657.htm(11): 808-813.
[29] Paranjpe I, Fuster V, Lala A, et al.Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19[J]. J Am Coll Cardiol, 2020, 76(1): 122-124.
[30] Moores LK, Tritschler T, Brosnahan S, et al.Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report[J]. Chest, 2020, 158(3): 1143-1163.
[31] Bikdeli B, Madhavan MV, Jimenez D, et al.COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(23): 2950-2973.
[32] Lemos ACB, do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)[J]. Thromb Res, 2020, 196: 359-366.
[33] Prandoni P, Cattelan AM, Carrozzi L, et al.The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin[J]. Thromb Res, 2020, 196: 395-397.
[34] Kirkup C, Pawlowski C, Puranik A, et al.Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry[J]. J Med Virol, 2021, 93(7): 4303-4318.
[35] Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al.Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients[J]. EClinicalMedicine, 2021, 33: 100774.
[36] Bikdeli B, Madhavan MV, Gupta A, et al.Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research[J]. Thromb Haemost, 2020, 120(7): 1004-1024.
[37] Li W, Xu Z, Xiang H, et al.Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status[J]. Aging (Albany NY), 2021, 13(7): 9225-9242.
[38] Farkouh ME, Stone GW, Lala A, et al.Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2022, 79(9): 917-928.